745233F1-DF41-4DDA-9146-1666DD59355E
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 65.7030223390276
- age_years
- 54
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.567
- E2F_TARGETS+0.527
- MYC_TARGETS_V1+0.516
- TGF_BETA_SIGNALING+0.504
- NOTCH_SIGNALING+0.492
- MITOTIC_SPINDLE+0.477
- WNT_BETA_CATENIN_SIGNALING+0.477
- INTERFERON_ALPHA_RESPONSE+0.369
- PROTEIN_SECRETION+0.367
- DNA_REPAIR+0.360
Top 10 suppressed
- KRAS_SIGNALING_DN-0.414
- MYOGENESIS-0.201
- PANCREAS_BETA_CELLS-0.178
- APICAL_SURFACE-0.151
- SPERMATOGENESIS-0.150
- COAGULATION-0.136
- ESTROGEN_RESPONSE_LATE-0.108
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.095
- HYPOXIA-0.045
- TNFA_SIGNALING_VIA_NFKB-0.045
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 4BB9587B-88CB-4BD9-BE1D-2CDF61337579 | — | — | 0.926 |
| 2 | 7604968C-689A-458D-96BA-33B163B238F8 | — | — | 0.926 |
| 3 | SRR934975 | — | — | 0.922 |
| 4 | 0F8BE394-BA6A-401C-87D0-9B3CF50FB0C8 | — | — | 0.922 |
| 5 | 67B2F9CD-759E-4300-8F4B-1B5C4F9E0B1C | — | — | 0.920 |
| 6 | 4099642A-F8D6-428C-AA12-1E76C27BB368 | — | — | 0.919 |
| 7 | EFB459E3-9B6A-4020-8556-6409065823B7 | — | — | 0.919 |
| 8 | AB522ACF-5D84-41B0-9671-CE2511EBD94F | — | — | 0.914 |
| 9 | 8BA4F4D7-5FCD-42B8-B000-108067FE6885 | — | — | 0.914 |
| 10 | F226F6D3-DE88-4B15-A0F1-63EDB55E8F9D | — | — | 0.912 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.567 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.527 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.516 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.504 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.492 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.477 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.477 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.369 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.367 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.360 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.346 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.323 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.291 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.278 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.260 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.250 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.221 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.220 | Temsirolimus | — uncovered |
| MTORC1_SIGNALING | 0.211 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |